Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 6/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.36 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.36 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.36 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295947 | 0.90 | GPR119 (0.48) | GPR119GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1296337 | 0.85 | GPR119 (0.46) | DEGS1ENPP2GPR119PPARGPPARD | |
| SCHEMBL12106761 | 0.85 | GUCY1B2 (0.38) | GPR119GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1296129 | 0.83 | GPR119 (0.39) | ENPP2GPR119GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL1295965 | 0.82 | ACACB (0.41) | DEGS1ENPP2GPR119PDE10APPARG | |
| SCHEMBL1296187 | 0.80 | GPR119 (0.48) | GPR119 | |
| SCHEMBL1713311 | 0.80 | CNR2 (0.36) | GPR119GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1713055 | 0.79 | GPR119 (0.44) | GPR119GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL1296024 | 0.79 | ITGB3 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL1296281 | 0.78 | GPR119 (0.46) | DEGS1ENPP2GPR119PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | DEGS1 1214/4885TACR3 321/4885ENPP2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.